Back to top
more

Assembly Biosciences (ASMB)

(Real Time Quote from BATS)

$16.20 USD

16.20
19,894

-0.69 (-4.09%)

Updated Nov 4, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Assembly Biosciences (ASMB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.98% and 27.73%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?

by Zacks Equity Research

Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.

What's in Store for Thermo Fisher (TMO) in Q3 Earnings?

by Zacks Equity Research

Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.

Top Ranked Momentum Stocks to Buy for October 18th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 18th

Will Assembly Biosciences Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Assembly Biosciences.

Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 34.55% and -20.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.87% and 1.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects

by Zacks Equity Research

Continued price erosion and intensifying competition in generic drug market is negatively impacting the top line of industry participants. However, stabilizing outlook is encouraging.

    Mylan (MYL) Jumps: Stock Rises 7.1%

    by Zacks Equity Research

    Mylan (MYL) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

    Amphastar Pharmaceuticals (AMPH) Catches Eye: Stock Jumps 6.7%

    by Zacks Equity Research

    Amphastar Pharmaceuticals (AMPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

      Assembly Biosciences (ASMB) Reports Q3 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.71% and 33.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

      Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

      by Zacks Equity Research

      Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Options Traders Expect Huge Moves in Assembly Biosciences (ASMB) Stock

      by Zacks Equity Research

      Assembly Biosciences (ASMB) needs investors to pay close attention to the stock based on moves in the options market lately.

        Assembly Biosciences (ASMB) Reports Q2 Loss, Misses Revenue Estimates

        by Zacks Equity Research

        Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -44.44% and -2.49%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          Zacks.com featured highlights: H&E Equipment Services, Nomad Foods, Strayer Education, BioLife Solutions and Assembly Biosciences

          by Zacks Equity Research

          Zacks.com featured highlights: H&E Equipment Services, Nomad Foods, Strayer Education, BioLife Solutions and Assembly Biosciences

            New Analyst Coverage Puts the Spotlight on These 5 Stocks

            by Zacks Equity Research

            Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

              New Strong Sell Stocks for September 18th

              by Zacks Equity Research

              Here are 4 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                New Strong Sell Stocks for August 31st

                by Zacks Equity Research

                Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                  New Strong Sell Stocks for August 16th

                  by Zacks Equity Research

                  Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                    Assembly Biosciences (ASMB) Looks Good: Stock Up 13.9%

                    by Zacks Equity Research

                    Assembly Biosciences, Inc. (ASMB) was a big mover last session, as the company saw its shares rise nearly 14% on the day.